Biovica has strengthened the company’s presence in the  United States by adding Edward M. (Ted) Suh, Ph.D. as Senior Director, US Business Development.

Ted received a B.A. degree in chemistry from Yale University, and a Ph.D. degree from Harvard University,  also in chemistry.  Prior to joining Biovica, Ted worked as a medicinal chemist at Glaxo.  Following this, he worked in drug discovery research at Eisai Inc, where he took on various interdisciplinary management and leadership roles for units in the U.S. and Japan, advancing drug discovery in the areas of oncology, inflammation and neurodegenerative disease. With over 20 years of experience in pharmaceutical research, Ted will be key for Biovica to increase the number of US collaboration partners and expand the ongoing trial programs for DiviTum, addressing applications as a predictive and response biomarker for cell-cycle regulating drugs.


“I am excited to be a part of the Biovica team.  DiviTum™ is a unique product that can help patients, caregivers and drug makers better address the diverse challenges that cancer presents.  I believe that researchers and pharmaceutical companies will embrace the promise of thymidine kinase as a translational biomarker in oncology.”

– Ted Suh, Senior Director, US Business Development


I’m very pleased that Ted joins our organisation. Ted has a personality and an experience that will be a huge contribution for Biovica. He’ll be focusing on developing new projects where DiviTum™ can improve the treatment for people living with cancer.”
– Anders Rylander, CEO of Biovica


Anders Rylander, CEO
Direct +46 (0) 18 44 44 835

Ted Suh, Senior Director, US Business Development
Phone: +1 (617) 939-9570